<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="editorial" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1222328</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2023.1222328</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Neurovascular dysfunction after brain injury</article-title>
<alt-title alt-title-type="left-running-head">Cheng et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2023.1222328">10.3389/fphar.2023.1222328</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Cheng</surname>
<given-names>Chongjie</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1620097/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Lei</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/941101/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guo</surname>
<given-names>Zongduo</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/943140/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Tunan</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1439999/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>The 1st Affiliated Hospital of Chongqing Medical University</institution>, <addr-line>Chongqing</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Loma Linda University Medical Center</institution>, <addr-line>Loma Linda</addr-line>, <addr-line>CA</addr-line>, <country>United States</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Southwest Hospital</institution>, <institution>Army Medical University</institution>, <addr-line>Chongqing</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited and reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3481/overview">Nicholas M. Barnes</ext-link>, University of Birmingham, United Kingdom</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Chongjie Cheng, <email>chengcj@hospital.cqmu.edu.cn</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>02</day>
<month>06</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1222328</elocation-id>
<history>
<date date-type="received">
<day>14</day>
<month>05</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>05</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Cheng, Huang, Guo and Chen.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Cheng, Huang, Guo and Chen</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="commentary-article" journal-id="Front. Pharmacol." xlink:href="https://www.frontiersin.org/researchtopic/45883" ext-link-type="uri">Editorial on the Research Topic <article-title>Neurovascular dysfunction after brain injury</article-title> </related-article>
<kwd-group>
<kwd>brain injury</kwd>
<kwd>vascular remodeling</kwd>
<kwd>vascular injury</kwd>
<kwd>neurovascular dysfunction</kwd>
<kwd>functional outcome</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Neuropharmacology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>Till now, our understanding of neurovascular dysfunction in brain injuries was greatly expanded. Emerging experimental investigations suggested vascular failure is one of the key pathogenic factors, which essentially underlies the damaging secondary events, featured in early capillary permeability disruption leading to cerebral edema, inflammation, and eventual neuron death. At delayed phases, vascular remodeling, particularly in angiogenesis and enhanced endothelial-derived trophic factor secretion, may promote endogenous neurogenesis and neural restoration. Hence, novel strategies targeting early and delayed neurovascular dysfunction, might provide promising opportunities to improve clinical outcomes for patients following brain injuries. The goal of this Research Topic is to concentrate on the recent findings in the pathophysiology, diagnosis, and potential therapeutic targets of neurovascular changes following brain injuries.</p>
<p>In the Research Topic, three excellent reviews presented the advances in the pathophysiology and prognosis of neurovascular events following serial brain injuries. <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2023.1125662/full">Luo et al.</ext-link> focused on the interaction between various components of the neurovascular unit and SUMOylation, and highlighted the importance of SUMOylation in neurovascular remodeling following acquired brain injury (ABI). <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2023.1124263/full">Eastin et al.</ext-link> summarized the clinical findings of delayed revascularization in acute ischemic stroke patients. The existing evidence supports improved outcomes after subacute revascularization beyond 4.5&#xa0;h of stroke onset in selected patients with favorable image characteristics. <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2023.1145605/full">Chen et al.</ext-link> systematically reviews the pathophysiological changes of myelin sheath injury after Subarachnoid hemorrhage (SAH). They proposed that the precise prevention and treatment of myelin injury should focus on the spatiotemporal characteristics of myelin sheath changes and the initiation, intersection, and common action points of pathophysiological mechanisms, emphasizing the big picture other than details, and actively exploring different treatment methods.</p>
<p>Moreover, the original researches provided the therapeutic targets for potential medical translation. <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2023.1091616/full">Chen et al.</ext-link> explored metabolomic alterations in mice after cerebral ischemia-reperfusion by employing metabolomic analysis coupling with GC-TOF-MS and UPLC/Q-TOF-MS. Their results showed several simultaneously differentially expressed metabolites and enriched pathways were significantly altered following ischemia-reperfusion. These varied metabolites are important for determining the cellular pathologic status of neuronal cells and their viability, and might be developed as potential molecular markers that can be helpful for therapeutic decision-making. <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2023.1098228/full">Ma et al.</ext-link> explored the therapeutic effects of 9-phenanthrol after traumatic brain injury (TBI) in rats, and found that it hinders the expression and activity of MMP-9 by impeding TRPM4 channel and represses the destruction of BBB, thereby preventing vasogenic brain edema. <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fgene.2022.1079455/full">Xu et al.</ext-link> performed a case-control study to investigate the correlation between DNA methylation and mRNA expression of the glutathione S-transferase alpha 4 (GSTA4) gene and the risk of intracranial aneurysm (IA) in the Chinese Han population. Their results suggested that GSTA4 methylation and mRNA expression may be reliable predictive markers of the occurrence of female IA.</p>
<p>Hopefully, the studies addressing our Research Topic will help understand the mechanisms underlying neurovascular dysfunction after brain injuries, and may provide promising targets to improve clinical outcomes in patients.</p>
</body>
<back>
<sec id="s1">
<title>Author contributions</title>
<p>All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.</p>
</sec>
<sec sec-type="COI-statement" id="s2">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s3">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</back>
</article>